Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pirenoxine sodium eye drops and solution for eye administration

A technology of pirenoxine sodium and eye drops, applied in the field of medicine

Active Publication Date: 2021-05-21
湖北远大天天明制药有限公司
View PDF8 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] However, the current pirenoxine sodium preparations still need to be improved

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pirenoxine sodium eye drops and solution for eye administration
  • Pirenoxine sodium eye drops and solution for eye administration
  • Pirenoxine sodium eye drops and solution for eye administration

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0051] Embodiment 1 prepares test solution

[0052] In this example, according to the method described in the general method, a series of solutions for dissolving pirenoxine sodium tablets and pirenoxine sodium tablets were prepared, and a series of test solutions were obtained by mixing and dissolving, as follows:

[0053] (1) Test solution A

[0054] The weight ratio of pirenoxine sodium to betamethasone is 1:0.13 (the concentration of pirenoxine sodium is 0.0053% by weight).

[0055] (2) Test Solution B

[0056] The weight ratio of pirenoxine sodium to hydrocortisone is 1:0.17 (the concentration of pirenoxine sodium is 0.0045% by weight).

[0057] (3) Test solution C

[0058] The weight content ratio of pirenoxine sodium to triamcinolone is 1:0.12 (the concentration of pirenoxine sodium is 0.0051% by weight).

[0059] (4) Test solution D

[0060] The weight content ratio of pirenoxine sodium-fluocinide is 1:0.29 (the concentration of pirenoxine sodium is 0.0055% by wei...

Embodiment 2

[0067] Embodiment 2 bioavailability test

[0068] "Bioavailability" refers to the extent and rate at which a drug is absorbed and utilized in target tissues. "Ocular bioavailability" refers more specifically to the concentration of a drug in the aqueous humor following topical administration of the drug comprising an aqueous eye drop composition.

[0069] Male albino rabbits of the New Zealand white strain were used, and one of the test solutions A-G was topically applied to one eye of each rabbit, and a reference solution (Bai Nei Ting) was applied to the other eye, wherein solutions A to E Pyrenol The concentration of pirenoxine sodium is the same as that of "Bai Nei Ting", while the concentration of pirenoxine sodium in solutions F and G is about 60% of that of "Bai Nei Ting".

[0070] Rabbits were sacrificed at various time points after dosing (5 animals were treated per time point) and aqueous humor samples were collected. The concentration of pirenoxine sodium was dete...

Embodiment 3

[0072] Example 3 Observation of postoperative capsule turbidity

[0073] 90 male albino rabbits of New Zealand white strain were continuously injected with d-galactose 125 mg / kg / day for 42 days to form a cataract model, and were randomly divided into three groups, 30 rabbits in each group, for extracapsular cataract extraction. The pirenoxine sodium eye drops (pirenoxine sodium-halometasone weight content ratio 1:0.13 (0.0053% by weight of pirenoxine sodium concentration)) given to the group after operation was instilled 2 times a day, 2 times each time. -4 drops, while the control group began to instill "Bai Nei Ting" eye drops on the third day after operation, while the control group was given normal saline, and 10 rabbits in each group were executed at 1, 2 and 3 months respectively. A total of 20 eyes, the eyeball specimens were taken and fixed with 10% formaldehyde, the intraocular lens was taken out, half of the eyeball was embedded in paraffin, sectioned, and stained wi...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides pirenoxine sodium eye drops. According to an embodiment of the invention, the pirenoxine sodium eye drops comprise a solvent, an anti-inflammatory agent, and a solid preparation, wherein the solid preparation contains pirenoxine sodium and pharmaceutically acceptable auxiliary materials. According to the embodiment of the invention, the pirenoxine sodium eye drops contain the anti-inflammatory agent and the pirenoxine sodium at the same time, so that the pirenoxine sodium eye drops can be applied to eye administration in the initial stage after an operation of a patient, the eye infection can be effectively prevented, the incidence rate of posterior capsule opacification after the operation can be reduced, especially, the occurrence rate of posterior capsule opacification after extracapsluar cataract extraction is reduced, the curing time of eye cataract of the patient can be shortened, the pain of the patient is reduced, and the living quality of the patient is improved.

Description

technical field [0001] The invention relates to the field of medicine, in particular to pirenoxine sodium eye drops and a solution for eye administration. Background technique [0002] Cataract is the first blinding eye disease in my country, accounting for more than 40% of blinding eye diseases. According to research, one of the reasons for the formation of cataract is that the soluble protein in the lens gradually becomes insoluble under the action of quinones. Quinone substances are formed by the abnormal metabolism of an important functional amino acid (tryptophan) in the body. [0003] Pirenoxine sodium (chemical name: 1-hydroxy-5-oxo-5H-pyrido-[3,2-]-phenoxazine-3-carboxylate sodium) can competitively inhibit the solubility of quinones to the lens In addition, pirenoxine sodium can also prevent or treat cataracts caused by free radical damage to the lens. Therefore, pirenoxine sodium has a certain inhibitory effect on the development of cataracts. [0004] According...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K9/08A61K9/20A61K31/5383A61K31/573A61K45/00A61P27/06
CPCA61K9/08A61K9/0048A61K9/2013A61K31/5383A61K31/573A61K45/00A61P27/06A61K2300/00
Inventor 付欢王超刘晨曦万利鹏延静尹传忠
Owner 湖北远大天天明制药有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com